Filing Analysis
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended June 30, 2026. The filing contains no substantive changes to corporate structure or material agreements.
π Key Facts
- The company issued a press release regarding financial results and business highlights on August 11, 2026.
- Reporting period is for the quarter ended June 30, 2026.
- The filing was signed by Kendra R. Adams, CFO.
C4 Therapeutics, Inc. held its Annual Meeting of Stockholders on June 24, 2026, reporting the results of four shareholder proposals including director elections and auditor ratification.
π Key Facts
- Elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors to hold office until 2029.
- Stockholders cast a non-binding advisory vote approving executive compensation (Say-on-Pay).
- Ratified KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Approved an amendment to the 2020 Stock Option and Incentive Plan regarding evergreen provisions and pre-funded warrants.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results and business highlights for the period ending September 30, 2025.
π Key Facts
- The filing was made on November 6, 2025.
- Reporting period: Quarter ended September 30, 2025.
- Content includes financial results and business highlights via Exhibit 99.1.
C4 Therapeutics released Phase 1 clinical trial data for cemsidomide in combination with dexamethasone for multiple myeloma. Additionally, the company terminated a specific sales agreement prospectus related to its common stock sale program with TD Securities (USA) LLC.
π© Red Flags
- Termination of a sales agreement prospectus suggests a pause or restructuring of their ATM (At-The-Market) equity offering capabilities.
π Key Facts
- Released Phase 1 clinical trial data for cemsidomide + dexamethasone for relapsed/refractory multiple myeloma on October 16, 2025.
- Terminated the sales agreement prospectus dated November 13, 2024, with TD Securities (USA) LLC.
- As of June 30, 2025, the company had sold 3,769,483 shares under the previous Sales Agreement, generating ~$9.6 million in gross proceeds.
C4 Therapeutics, Inc. entered into an underwriting agreement to conduct a significant equity offering involving common stock and multiple classes of warrants. The offering is expected to raise approximately $117 million in net proceeds, extending the company's cash runway through the end of 2028.
π© Red Flags
- Significant potential dilution due to the massive volume of warrants (over 100 million shares) accompanying the stock offering.
- Complex warrant structure including 'Pre-Funded Warrants' which are often used when investors want to avoid certain ownership thresholds or regulatory constraints.
π Key Facts
- Underwriters include Jefferies LLC, TD Securities (USA) LLC, and Evercore Group L.L.C.
- Offering includes 21,895,000 shares of common stock at $2.47 per share.
- Includes Pre-Funded Warrants for an aggregate of 28,713,500 shares (exercise price $0.0001).
- Includes Class A and Class B Warrants totaling 101,217,000 potential shares at an exercise price of $2.22.
- Estimated net proceeds from the offering: ~$117 million.
- Potential aggregate net proceeds if all warrants are exercised: ~$341.7 million.
- Expected closing date: October 17, 2025.
- Cash runway extension: Through end of 2028.
C4 Therapeutics entered into a clinical trial collaboration and supply agreement with Pfizer Inc. to evaluate the combination of cemsidomide and dexamethasone with Pfizer's elranatamab for multiple myeloma.
π Key Facts
- Agreement dated October 1, 2025.
- Pfizer will supply elranatamab (ELREXFIO) at no cost to C4 Therapeutics.
- C4 Therapeutics will sponsor and conduct a Phase 1b trial evaluating the safety and tolerability of cemsidomide + dexamethasone + elranatamab.
- The trial targets second-line or later therapy for patients with multiple myeloma.
- Pfizer receives access to clinical trial data in exchange for the drug supply.
C4 Therapeutics, Inc. issued an 8-K to announce the presentation of Phase 1 clinical trial data for cemsidomide in combination with dexamethasone at the International Myeloma Society Annual Meeting.
π Key Facts
- Clinical trial focus: Phase 1 study of cemsidomide (an orally bioavailable IKZF1/3 degrader) + dexamethasone.
- Indication: Treatment of relapsed/refractory multiple myeloma (RRMM).
- Event date: Data presented on September 20, 2025, at the IMS Meeting.
- Filing date: September 22, 2025.
C4 Therapeutics announced its Q2 2025 financial results and provided clinical updates for its lead candidate, cemsidomide. The company reported positive Phase 1 data in multiple myeloma (MM) and non-Hodgkinβs Lymphoma (NHL), noting compelling response rates.
π© Red Flags
- Forward-looking statements include risks regarding the ability to fund future operations and the availability of capital.
π Key Facts
- Completed enrollment and dose escalation for the Phase 1 trial of cemsidomide in MM and NHL as of July 23, 2025.
- Reported an overall response rate (ORR) of 40% at the 75 ΞΌg dose level and 50% at the 100 ΞΌg dose level for cemsidomide plus dexamethasone in MM.
- Expects to align with the FDA on a recommended Phase 2 dose by year-end 2025.
- Aims to initiate registrational development of cemsidomide in early 2026.
- Announced Q2 2025 financial results via press release (Exhibit 99.1).
C4 Therapeutics held its Annual Meeting of Stockholders on June 18, 2025, where stockholders approved several key items including the election of directors and an increase in authorized shares. The meeting also included the ratification of KPMG LLP as the independent auditor.
π© Red Flags
- Significant increase in authorized shares (doubled from 150M to 300M), which can be a precursor to future equity dilution via secondary offerings.
π Key Facts
- Annual Meeting held on June 18, 2025.
- Stockholders approved an amendment to increase authorized common stock from 150,000,000 to 300,000,000 shares.
- Ronald Harold Wilfred Cooper, Donna Grogan, M.D., and Steven Hoerter were elected as Class II directors.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Advisory vote to approve executive officer compensation was passed.
C4 Therapeutics announced its Q1 2025 financial results and provided clinical updates for its Phase 1 trial of cemsidomide. The company reported positive topline data in multiple myeloma, including a 50% ORR at the 100 ΞΌg QD dose level.
π© Red Flags
- Forward-looking statements include risks regarding the ability to fund future operations (standard biotech risk).
π Key Facts
- Phase 1 dose escalation for cemsidomide in multiple myeloma (MM) is complete; 100 ΞΌg QD dose declared safe for expansion.
- In MM, 10 patients at the 100 ΞΌg QD dose level achieved a 50% Overall Response Rate (ORR).
- One patient in the 100 ΞΌg QD cohort achieved minimal residual disease negative complete response after progressing on two prior T-cell engager therapies.
- At the 75 ΞΌg QD dose level, 20 patients have been treated with a 40% ORR as of April 30, 2025.
- Non-Hodgkinβs lymphoma arm is ongoing at the 87.5 ΞΌg QD dose level; maximum tolerated dose not yet reached.
- Company expects regulatory feedback on registrational development for cemsidomide by mid-year 2025.
C4 Therapeutics, Inc. announced that Bruce Downey will retire from the Board of Directors and not stand for reelection at the 2025 Annual Meeting of Stockholders. The departure is characterized as a retirement without disagreement with the company's strategy or operations.
π Key Facts
- Bruce Downey notified the Board on April 10, 2025, of his intention to retire.
- He will not stand for reelection at the 2025 Annual Meeting of Stockholders.
- Upon retirement, he will cease serving as a director and member of the Organization, Leadership and Compensation Committee; Audit Committee; and Nominating and Corporate Governance Committee.
- The company explicitly stated the departure is not due to any disagreements regarding strategy, operations, policies, or practices.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ended December 31, 2024. The filing serves as a formal announcement of business highlights and financial performance via a press release.
π Key Facts
- Reported date: February 27, 2025
- Reporting period: Quarter and fiscal year ended December 31, 2024
- The filing includes Exhibit 99.1 (Press Release) containing financial results and business highlights.
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
C4 Therapeutics disclosed its preliminary cash position as of December 31, 2024, stating that current liquid assets are sufficient to fund operations into 2027. The company also announced upcoming presentations at the J.P. Morgan Healthcare Conference.
π© Red Flags
- Information is unaudited and preliminary; actual cash position could change following the completion of the annual audit.
π Key Facts
- Unaudited cash, cash equivalents, and marketable securities as of Dec 31, 2024, are expected to fund operations into 2027.
- The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.
- Financial data provided is preliminary and subject to ongoing audit for the fiscal year ended Dec 31, 2024.
C4 Therapeutics presented clinical updates for its cemsidomide Phase 1/2 trial at the American Society of Hematology (ASH) Annual Meeting. The filing includes a press release and corporate presentation detailing data related to multiple myeloma and non-Hodgkinβs lymphoma.
π Key Facts
- Presented clinical update at ASH Annual Meeting on December 8, 2024.
- Reported Phase 1/2 trial data for cemsidomide in multiple myeloma and non-Hodgkinβs lymphoma.
- Published updated corporate presentation and press release via Exhibit 99.1, 99.2, and 99.3.
C4 Therapeutics, Inc. announced the appointment of Steven L. Hoerter to its Board of Directors on November 19, 2024. Mr. Hoerter will serve as a Class II director and has been granted stock options for up to 65,000 shares.
π Key Facts
- Steven L. Hoerter appointed as Director on November 19, 2024.
- Designated as a Class II director serving until the 2025 Annual Meeting of Stockholders.
- Board determined Mr. Hoerter is independent under Nasdaq listing standards.
- Granted stock options to purchase up to 65,000 shares of common stock under the 2020 Stock Option and Incentive Plan.
- Vesting schedule: One-third on the first anniversary; remainder vests quarterly over the subsequent two years.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results and business highlights for the period ended September 30, 2024.
π Key Facts
- The filing is a standard disclosure of quarterly results (Item 2.02).
- Financial results and business highlights were announced via press release on October 31, 2024.
- The report was signed by Kendra R. Adams, Chief Financial Officer.
C4 Therapeutics, Inc. announced the retirement of Chief Scientific Officer Dr. Stewart Fisher and the simultaneous appointment of Dr. Paige Mahaney as her successor. The filing is an amendment to a previous 8-K to correct dates regarding Dr. Fisher's retirement notification.
π© Red Flags
- Succession transition period involves a consulting agreement with the outgoing CSO that includes equity vesting through late 2025.
- Amendment filed to correct errors in the original filing regarding retirement notification dates.
π Key Facts
- Dr. Stewart Fisher notified the company of his intent to retire from the CSO role, effective when his successor joins (expected Oct 28, 2024).
- Dr. Fisher will serve as Senior Scientific Advisor through Dec 31, 2024, and a consultant/advisor through Dec 31, 2025.
- A Consulting Agreement was entered into on Oct 15, 2024; Dr. Fisher receives continued equity vesting through Dec 31, 2025 in exchange for advisory services.
- Dr. Paige Mahaney appointed as new CSO effective Oct 28, 2024, joining from Exelixis, Inc.
- Mahaney's compensation includes a $510,000 base salary, $150,000 sign-on bonus, and up to $75,000 relocation allowance.
- Material inducement for Mahaney includes an option to purchase 345,600 shares of common stock and 76,800 RSUs.
C4 Therapeutics announced a leadership transition in its scientific department, involving the retirement of Chief Scientific Officer Dr. Stewart Fisher and the appointment of Dr. Paige Mahaney as his successor.
π© Red Flags
- None identified; the departure is characterized as retirement without disagreement with management.
π Key Facts
- Dr. Stewart Fisher to retire as CSO effective October 28, 2024; will serve as Senior Scientific Advisor through Dec 31, 2024, and a consultant through Dec 31, 2025.
- Dr. Paige Mahaney appointed as new CSO, effective October 28, 2024.
- Dr. Mahaney joins from Exelixis, Inc., where she was SVP and Corporate Head of Drug Discovery.
- Mahaney's compensation includes a $510,000 base salary, $150,000 sign-on bonus, $75,000 relocation allowance, and performance bonuses up to 40%.
- Dr. Mahaney received a material inducement grant of up to 345,600 stock options and 76,800 RSUs.
C4 Therapeutics, Inc. announced an amendment to its 2020 Stock Option and Incentive Plan. The amendment restricts the Board's ability to reduce exercise prices or reprice options without prior stockholder approval.
π Key Facts
- Amendment No. 1 to the 2020 Stock Option and Incentive Plan was approved by the Board on October 7, 2024.
- The amendment prevents the Administrator from reducing exercise prices or repricing options through cancellation/re-grants without stockholder approval.
- The amendment is effective immediately and does not require stockholder approval.
C4 Therapeutics, Inc. announced the resignation of Director Malcolm Salter and the appointment of Stephen Fawell, Ph.D. to the Board effective August 29, 2024.
π© Red Flags
- None identified in this filing.
π Key Facts
- Malcolm Salter resigned from the Board effective August 29, 2024; no disagreements reported regarding company operations or policies.
- Stephen Fawell, Ph.D. appointed as a director and member of the Science and Technology Committee, designated as an independent Class III director.
- Dr. Fawell granted stock options for up to 65,000 shares under the 2020 Stock Option and Incentive Plan with a multi-year vesting schedule.
- Ronald Cooper appointed as chair of the Nominating and Corporate Governance (NCG) Committee; Bruce Downey appointed to the Audit Committee.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results and business highlights for the period ending June 30, 2024.
π Key Facts
- The filing is a standard earnings release under Item 2.02.
- Financial results cover the quarter ended June 30, 2024.
- The report was signed by Kendra R. Adams, CFO and Treasurer on August 1, 2024.
C4 Therapeutics, Inc. held its Annual Meeting of Stockholders on June 20, 2024. The meeting resulted in the election of three Class I directors and the ratification of KPMG LLP as the independent auditor.
π Key Facts
- Annual Meeting of Stockholders held on June 20, 2024.
- Elected Kenneth Anderson, M.D., Laura Bessen, M.D., and Owen Hughes as Class I directors to hold office until 2027.
- Stockholders cast a non-binding advisory vote (Say-on-Pay) approving executive compensation with 34,500,552 votes 'For'.
- Ratified the selection of KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024.
C4 Therapeutics, Inc. announced a leadership reorganization within its Board of Directors, including the resignation of Glenn Dubin and the appointment of Ron Cooper as the new Chair of the Board.
π© Red Flags
- None identified in this filing.
π Key Facts
- Glenn Dubin resigned from the Board effective upon his successor's appointment; no disagreements were reported.
- Ron Cooper appointed to the Board as a Class II director, serving until the 2025 Annual Meeting.
- Ron Cooper appointed as the new Chair of the Board, replacing Bruce Downey who remains on the Board and NCG Committee.
- Mr. Cooper granted stock options for up to 65,000 shares under the 2020 Stock Option and Incentive Plan.
- Effective June 7, 2024: Ron Cooper appointed Chair; Bruce Downey stepped down as Chair but remains a Director.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2024.
π Key Facts
- The filing reports financial results and business highlights for the quarter ended March 31, 2024.
- The report was filed on May 8, 2024.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
C4 Therapeutics, Inc. announced the repricing of underwater stock options for several key executive officers and employees on March 7, 2024. The repricing aims to incentivize retention by lowering exercise prices to levels closer to historical highs or the IPO price.
π© Red Flags
- Related-party transaction involving the repricing of options for multiple executive officers.
- Significant gap between current stock price (implied by 'underwater' status) and previous exercise prices, indicating poor recent performance.
- Potential dilution/incentive misalignment: Repricing can be viewed as a way to compensate executives despite declining shareholder value.
π Key Facts
- Effective Date: March 7, 2024.
- Eligible Options: Those with an exercise price greater than $22.00 per share.
- Executive Repricing: CFO (Kendra Adams), CBO (Scott Boyle), CSO (Kelly Schick), Chief People Officer, and CLO (Jolie Siegel) had options repriced to $19.00 per share (IPO price).
- General Employee Repricing: Other employees had options repriced to $11.88 per share (52-week high).
- Retention Period: Options revert to original prices if the holder is terminated for cause, resigns (except death/disability), or exercises them before March 7, 2025.
- Exclusions: CEO Andrew Hirsch and non-employee Board members were not eligible for repricing.
C4 Therapeutics entered into a significant research collaboration and license agreement with Merck KGaA (EMD Serono) to discover two targeted protein degraders. The deal includes an upfront payment of $16 million and potential milestone payments totaling approximately $740 million.
π© Red Flags
- Merck KGaA retains the right to terminate the agreement for convenience upon 60 days' notice, which limits C4T's long-term control over the assets.
π Key Facts
- Entered into License Agreement with Merck KGaA (operating as EMD Serono in the U.S./Canada) on March 1, 2024.
- Merck KGaA to fund C4T's discovery research efforts and cover all development, regulatory, manufacturing, and commercialization costs.
- Upfront cash payment of $16.0 million from Merck KGaA to C4T.
- C4T eligible for up to ~$740 million in aggregate milestone payments (discovery, regulatory, and commercial).
- Royalty terms: mid-single digit to low-double digit percent on net sales.
- Merck KGaA has the right to terminate for convenience with 60 days' notice.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ended December 31, 2023. The filing serves as a vehicle to distribute the company's earnings press release.
π Key Facts
- Reported date of earliest event: February 15, 2024
- Filing date: February 22, 2024
- Reporting period covered: Quarter and fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the press release with financial results.
C4 Therapeutics has furnished an investor presentation via Item 7.01, which includes forward-looking statements regarding the company's ongoing restructuring and cost-saving initiatives.
π© Red Flags
- Mention of an ongoing 'Restructuring' and associated charges/costs suggests significant operational changes or distress.
- Implicit focus on 'preserving cash runway' indicates a need for strict capital management.
π Key Facts
- Company posted an updated investor presentation to its website on January 11, 2024.
- The filing contains forward-looking statements concerning a 'Restructuring' process.
- Management expects the restructuring to preserve cash runway into 2027.
C4 Therapeutics announced a strategic restructuring involving a 30% reduction in workforce (approximately 45 positions) to optimize cost structure and focus on core clinical programs. The company expects to incur approximately $3 million in charges related to this restructuring, primarily in Q1 2024.
π© Red Flags
- Significant workforce reduction (30%) often indicates liquidity constraints or a pivot due to capital limitations.
- Immediate $3 million charge impact on upcoming quarterly earnings.
- Strategic shift suggests previous resource allocation was not meeting value creation goals.
π Key Facts
- Restructuring involves a reduction of approximately 30% of the workforce (45 positions).
- Estimated restructuring charges are approximately $3 million, mostly to be recognized in Q1 2024.
- The company is shifting focus to CFT7455 (Phase 1/2 clinical trial) and CFT1946 (Phase 1/2 clinical trial).
- Management expects the restructuring to preserve cash runway into 2027.
- Reductions are expected to be substantially complete by the end of Q1 2024.